Valuation: Bioventix PLC

Market Cap 99.79M 133M 119M 110M 188M 12.65B 191M 1.32B 519M 6.62B 501M 490M 21.11B P/E 2026 *
14x
P/E 2027 * -
Enterprise Value 94.89M 127M 113M 105M 178M 12.03B 181M 1.26B 494M 6.29B 476M 466M 20.08B EV / Sales 2026 *
7.59x
EV / Sales 2027 * -
Free-Float
92.29%
Yield 2026 *
7.85%
Yield 2027 * -
1 day+7.91%
1 week+5.52%
Current month+12.35%
1 month+24.03%
3 months+23.23%
6 months+6.11%
Current year+0.26%
1 week 1,650
Extreme 1650
2,000
1 month 1,500
Extreme 1500
2,000
Current year 1,300
Extreme 1300
2,000
1 year 1,300
Extreme 1300
2,450
3 years 1,300
Extreme 1300
5,100
5 years 1,300
Extreme 1300
5,100
10 years 26.51
Extreme 26.51
5,100
Manager TitleAgeSince
Chief Executive Officer 67 2003-12-22
Director of Finance/CFO 67 2020-06-30
Director TitleAgeSince
Director/Board Member 67 2010-11-24
Chairman 66 2004-10-31
Director/Board Member 67 2020-06-30
Date Insider Type Main position Quantity % Market Cap. Importance
4/28/26 Buy

Chief Financial Officer

66 0.0013%
4/20/26 Free

Chief Executive Officer

9,967 0.1908%
4/20/26 Free

Chief Financial Officer

9,967 0.1908%
Change 5-day change 1-year change 3-year change Capi.($)
+7.91%+5.52%-21.72%-47.31% 123M
+0.79%-6.46%+52.86%+71.34% 65.83B
+1.92%+8.89%+12.90%+82.75% 51.87B
+6.91%+6.41%+9.61%+73.07% 51.2B
+0.74%+2.15%+30.95%+43.43% 43.76B
+3.87%+9.73%+21.52%+142.33% 42.09B
+7.91%+1.34%+263.31%+577.76% 39.04B
-0.40%+9.42%+18.44%+59.06% 34B
+3.84%-4.94%+42.35%+8.92% 25.2B
+2.36%+4.62%+24.20%+31.02% 22.8B
Average +3.60%+1.38%+45.44%+104.24% 37.59B
Weighted average by Cap. +3.08%+0.62%+51.67%+122.66%

Financials

2026 *2027 *
Net sales 12.5M 16.72M 14.88M 13.79M 23.49M 1.58B 23.89M 166M 65.02M 829M 62.72M 61.42M 2.64B -
Net income 7.1M 9.5M 8.45M 7.84M 13.34M 900M 13.57M 94.02M 36.93M 471M 35.63M 34.89M 1.5B -
Net Debt -4.9M -6.55M -5.83M -5.41M -9.21M -621M -9.36M -64.88M -25.49M -325M -24.59M -24.08M -1.04B -
Projected Income Statement - Annual - Bioventix PLC
Logo Bioventix PLC
Bioventix plc is a United Kingdom-based company specializing in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, such as automated immunoassays used in blood testing. The antibodies created at the Company are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. It offers a portfolio of antibodies to customers for both commercial use and research and development purposes, for the diagnosis or monitoring of a range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. The Company’s products include sheep monoclonal antibodies (SMAs), Pyrene (HOP-G) ELISA Kits, and Pyrene (HOP-G) Lateral Flow Kits. The Company supplies antibody products and services to the majority of multinational clinical diagnostics companies.
Employees
12
Date Price Change Volume
26-10-20 GBX 1,910.00 +7.91% 21,640
26-10-19 GBX 1,770.00 -1.67% 24,818
26-10-16 GBX 1,800.00 +2.86% 7,548
26-10-15 GBX 1,750.00 0.00% 12,074
26-10-14 GBX 1,750.00 +4.48% 14,323
Trader
Investor
-
Global
-
Quality
ESG MSCI
CCC
MarketScreener Ratings - Bioventix PLC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
19.10GBP
Average target price
39.00GBP
Spread / Average Target
+104.19%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Bioventix PLC
  1. Stock Market
  2. Stocks
  3. BVXP Stock